BR112019003989A2 - métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado - Google Patents
métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativadoInfo
- Publication number
- BR112019003989A2 BR112019003989A2 BR112019003989A BR112019003989A BR112019003989A2 BR 112019003989 A2 BR112019003989 A2 BR 112019003989A2 BR 112019003989 A BR112019003989 A BR 112019003989A BR 112019003989 A BR112019003989 A BR 112019003989A BR 112019003989 A2 BR112019003989 A2 BR 112019003989A2
- Authority
- BR
- Brazil
- Prior art keywords
- coagulation factor
- activated
- bleeding
- recognizes
- blood clotting
- Prior art date
Links
- 102000013831 Coagulation factor IX Human genes 0.000 title 2
- 102100029117 Coagulation factor X Human genes 0.000 title 2
- 108010076282 Factor IX Proteins 0.000 title 2
- 108010014173 Factor X Proteins 0.000 title 2
- 229940105774 coagulation factor ix Drugs 0.000 title 2
- 229940105756 coagulation factor x Drugs 0.000 title 2
- 238000000034 method Methods 0.000 title 1
- 230000000740 bleeding effect Effects 0.000 abstract 6
- 239000003114 blood coagulation factor Substances 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
a presente invenção tem por objetivo prover uma composição farmacêutica eficaz ou um regime de dosagem para prevenção e/ou tratamento de sangramento de uma doença acompanhada de sangramento ou uma doença causada por sangramento. os inventores descobriram que, com a administração de uma composição farmacêutica compreendendo uma molécula biespecífica de ligação ao antígeno que reconhece (a) fatores de coagulação sanguínea ix e/ou fatores de coagulação sanguínea ix ativados e (b) fatores de coagulação sanguínea x e/ou fatores de coagulação sanguínea x ativados, de acordo com um dado regime de dosagem, o sangramento, uma doença acompanhada de sangramento ou uma doença causada por sangramento podem ser prevenidos e/ou tratados de forma mais eficaz.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662383933P | 2016-09-06 | 2016-09-06 | |
US201662437281P | 2016-12-21 | 2016-12-21 | |
US201762485514P | 2017-04-14 | 2017-04-14 | |
PCT/JP2017/031933 WO2018047813A1 (en) | 2016-09-06 | 2017-09-05 | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019003989A2 true BR112019003989A2 (pt) | 2019-05-28 |
Family
ID=61561893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019003989A BR112019003989A2 (pt) | 2016-09-06 | 2017-09-05 | métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado |
Country Status (16)
Country | Link |
---|---|
US (4) | US11352438B2 (pt) |
EP (1) | EP3509637A4 (pt) |
JP (2) | JP7125932B2 (pt) |
KR (2) | KR102560808B1 (pt) |
CN (1) | CN109661241A (pt) |
AU (1) | AU2017325240A1 (pt) |
BR (1) | BR112019003989A2 (pt) |
CA (1) | CA3035327A1 (pt) |
CR (1) | CR20190162A (pt) |
IL (1) | IL265144B1 (pt) |
MA (1) | MA46200A (pt) |
MX (1) | MX2019002510A (pt) |
RU (1) | RU2766233C2 (pt) |
SG (1) | SG11201901961SA (pt) |
TW (1) | TWI786061B (pt) |
WO (1) | WO2018047813A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI609698B (zh) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | 穩定化的含抗體溶液製劑 |
PT2644698T (pt) | 2010-11-17 | 2018-01-31 | Chugai Pharmaceutical Co Ltd | Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue |
SG11201901961SA (en) | 2016-09-06 | 2019-04-29 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
US11787874B2 (en) | 2017-11-15 | 2023-10-17 | Novo Nordisk A/S | Factor X binders enhancing FX activation |
FR3082427B1 (fr) | 2018-06-14 | 2020-09-25 | Lab Francais Du Fractionnement | Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x |
CA3123177A1 (en) | 2018-12-21 | 2020-06-25 | Kymab Limited | Fixaxfx bispecific antibody with common light chain |
IL292106A (en) * | 2019-10-11 | 2022-06-01 | Chugai Pharmaceutical Co Ltd | A pharmaceutical composition that can be used to prevent and/or treat acquired hemophilia a, and a product that includes this pharmaceutical composition |
WO2021070885A1 (ja) * | 2019-10-11 | 2021-04-15 | 中外製薬株式会社 | 後天性血友病aの予防および/または治療に用いられる医薬組成物、および当該医薬組成物を含む製品 |
USD967377S1 (en) | 2020-10-08 | 2022-10-18 | Samsung Electronics Co., Ltd. | Air purifier |
KR20230130558A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 월 1회 투여 방법 |
KR20230130561A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법 |
KR20230130560A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 주 1회 투여 방법 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
IL89491A0 (en) | 1988-11-17 | 1989-09-10 | Hybritech Inc | Bifunctional chimeric antibodies |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ATE177321T1 (de) | 1989-12-11 | 1999-03-15 | Immunomedics Inc | Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper |
TW212184B (pt) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
JPH05184383A (ja) | 1990-06-19 | 1993-07-27 | Dainabotsuto Kk | 二重特異性抗体 |
JPH05199894A (ja) | 1990-08-20 | 1993-08-10 | Takeda Chem Ind Ltd | 二重特異性抗体および抗体含有薬剤 |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
JPH05304992A (ja) | 1991-06-20 | 1993-11-19 | Takeda Chem Ind Ltd | ハイブリッド・モノクローナル抗体および抗体含有薬剤 |
JPH06104071A (ja) | 1991-08-30 | 1994-04-15 | Jasco Corp | 発熱体セラミックス溶接加工方法 |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
JPH05203652A (ja) | 1992-01-28 | 1993-08-10 | Fuji Photo Film Co Ltd | 抗体酵素免疫分析法 |
JPH05213775A (ja) | 1992-02-05 | 1993-08-24 | Otsuka Pharmaceut Co Ltd | Bfa抗体 |
US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
US5744446A (en) | 1992-04-07 | 1998-04-28 | Emory University | Hybrid human/animal factor VIII |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
EP0660937A1 (en) | 1993-07-01 | 1995-07-05 | Dade International Inc. | Process for the preparation of factor x depleted plasma |
FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
EP0771216B9 (en) | 1994-07-11 | 2003-01-02 | The Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of tumoral vasculature |
AU701342B2 (en) | 1994-07-13 | 1999-01-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
EP1241264A1 (en) | 1994-12-02 | 2002-09-18 | Chiron Corporation | Monoclonal antibodies to colon cancer antigen |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
JP3032287U (ja) | 1996-06-10 | 1996-12-17 | 幸喜 高橋 | 人 形 |
JPH10165184A (ja) | 1996-12-16 | 1998-06-23 | Tosoh Corp | 抗体、遺伝子及びキメラ抗体の製法 |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
CA2288600C (en) | 1997-05-02 | 2010-06-01 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
DE19725586C2 (de) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
BR9909382A (pt) | 1998-04-03 | 2000-12-05 | Chugai Pharmaceutical Co Ltd | Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado |
AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
US20020103345A1 (en) | 2000-05-24 | 2002-08-01 | Zhenping Zhu | Bispecific immunoglobulin-like antigen binding proteins and method of production |
WO2002006838A1 (fr) | 2000-07-17 | 2002-01-24 | Chugai Seiyaku Kabushiki Kaisha | Methode de criblage d'un ligand dote d'une activite biologique |
WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
AU2002213441B2 (en) | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
AU1091802A (en) | 2000-10-20 | 2002-04-29 | Chugai Pharmaceutical Co Ltd | Degraded agonist antibody |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
DE10156482A1 (de) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
JP4386741B2 (ja) | 2002-04-15 | 2009-12-16 | 中外製薬株式会社 | scDbライブラリーの作成方法 |
US7732149B2 (en) | 2002-04-26 | 2010-06-08 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening agonistic antibodies |
ES2368733T3 (es) | 2002-07-18 | 2011-11-21 | Merus B.V. | Producción recombinante de mezclas de anticuerpos. |
JPWO2004060919A1 (ja) | 2002-12-26 | 2006-05-11 | 中外製薬株式会社 | ヘテロ受容体に対するアゴニスト抗体 |
DE602004021095D1 (de) | 2003-01-21 | 2009-06-25 | Chugai Pharmaceutical Co Ltd | Verfahren zum screening der leichten kette eines antikörpers |
US8765124B2 (en) | 2003-02-28 | 2014-07-01 | Chugai Seiyaku Kabushiki Kaisha | Stabilized preparation containing protein |
GB2400851B (en) | 2003-04-25 | 2004-12-15 | Bioinvent Int Ab | Identifying binding of a polypeptide to a polypeptide target |
US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
AU2003271186A1 (en) | 2003-10-14 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
JP4460414B2 (ja) | 2004-10-06 | 2010-05-12 | 日本電信電話株式会社 | 血圧計 |
ES2592271T3 (es) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos |
US20100003254A1 (en) | 2005-04-08 | 2010-01-07 | Chugai Seiyaku Kabushiki Kaisha | Antibody Substituting for Function of Blood Coagulation Factor VIII |
EP4218801A3 (en) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
EP4342995A3 (en) | 2006-03-31 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
WO2009041643A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
ES2777901T3 (es) | 2009-12-25 | 2020-08-06 | Chugai Pharmaceutical Co Ltd | Método de modificación de polipéptidos para purificar multímeros polipeptídicos |
TWI609698B (zh) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | 穩定化的含抗體溶液製劑 |
BR112012031920A2 (pt) | 2010-06-14 | 2017-05-16 | Paion Deutschland Gmbh | tratamento de coagulopatias com hiperfibrinólise. |
PT2644698T (pt) | 2010-11-17 | 2018-01-31 | Chugai Pharmaceutical Co Ltd | Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue |
BR112014019667B1 (pt) | 2012-03-08 | 2022-11-01 | F. Hoffmann-La Roche Ag | Formulação farmacêutica líquida estável de anticorpo abeta |
US10407488B2 (en) | 2013-11-04 | 2019-09-10 | The Regents Of The University Of California | Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation |
TW201625299A (zh) | 2014-06-20 | 2016-07-16 | Chugai Pharmaceutical Co Ltd | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
AU2016245887B2 (en) | 2015-04-10 | 2021-09-23 | Adimab, Llc. | Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species |
KR102057767B1 (ko) | 2015-04-17 | 2019-12-19 | 에프. 호프만-라 로슈 아게 | 응고 인자 및 다중특이적 항체의 조합 요법 |
JP2018123055A (ja) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | 血液凝固第viii因子(fviii)の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第xi因子(fxi)異常症の予防および/または治療に用いられる医薬組成物 |
JOP20170017B1 (ar) | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
JP7320943B2 (ja) | 2016-04-28 | 2023-08-04 | 中外製薬株式会社 | 抗体含有製剤 |
SG11201901961SA (en) | 2016-09-06 | 2019-04-29 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
EP3603670A4 (en) | 2017-03-31 | 2021-03-10 | Public University Corporation Nara Medical University | MEDICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BLOOD CLOG FACTOR IX ANOMALY WITH A MULTI-SPECIFIC ANTIGIBINDING MOLECULAR FUNCTION OF BLOOD CLOTHING FACTOR VIII |
CN111479829A (zh) | 2017-11-01 | 2020-07-31 | 中外制药株式会社 | 具有降低的生物活性的抗体变体和同种型 |
WO2021070885A1 (ja) | 2019-10-11 | 2021-04-15 | 中外製薬株式会社 | 後天性血友病aの予防および/または治療に用いられる医薬組成物、および当該医薬組成物を含む製品 |
-
2017
- 2017-09-05 SG SG11201901961SA patent/SG11201901961SA/en unknown
- 2017-09-05 IL IL265144A patent/IL265144B1/en unknown
- 2017-09-05 JP JP2019511669A patent/JP7125932B2/ja active Active
- 2017-09-05 RU RU2019109464A patent/RU2766233C2/ru active
- 2017-09-05 BR BR112019003989A patent/BR112019003989A2/pt unknown
- 2017-09-05 WO PCT/JP2017/031933 patent/WO2018047813A1/en unknown
- 2017-09-05 AU AU2017325240A patent/AU2017325240A1/en active Pending
- 2017-09-05 TW TW106130277A patent/TWI786061B/zh active
- 2017-09-05 MX MX2019002510A patent/MX2019002510A/es unknown
- 2017-09-05 CA CA3035327A patent/CA3035327A1/en active Pending
- 2017-09-05 CR CR20190162A patent/CR20190162A/es unknown
- 2017-09-05 US US16/330,269 patent/US11352438B2/en active Active
- 2017-09-05 KR KR1020197009689A patent/KR102560808B1/ko active IP Right Grant
- 2017-09-05 MA MA046200A patent/MA46200A/fr unknown
- 2017-09-05 EP EP17848753.4A patent/EP3509637A4/en active Pending
- 2017-09-05 KR KR1020237025275A patent/KR20230117462A/ko not_active Application Discontinuation
- 2017-09-05 CN CN201780054106.1A patent/CN109661241A/zh active Pending
-
2022
- 2022-05-31 US US17/828,752 patent/US20220315667A1/en not_active Abandoned
- 2022-08-15 JP JP2022129184A patent/JP2022166174A/ja active Pending
-
2023
- 2023-01-19 US US18/156,559 patent/US20230159658A1/en not_active Abandoned
- 2023-09-14 US US18/466,900 patent/US20240052058A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL265144A (pt) | 2019-04-30 |
RU2766233C2 (ru) | 2022-02-10 |
SG11201901961SA (en) | 2019-04-29 |
IL265144B1 (en) | 2024-06-01 |
EP3509637A4 (en) | 2020-05-27 |
US11352438B2 (en) | 2022-06-07 |
US20220315667A1 (en) | 2022-10-06 |
US20190194352A1 (en) | 2019-06-27 |
RU2019109464A3 (pt) | 2020-12-21 |
KR20230117462A (ko) | 2023-08-08 |
AU2017325240A1 (en) | 2019-05-02 |
US20240052058A1 (en) | 2024-02-15 |
JP7125932B2 (ja) | 2022-08-25 |
JP2022166174A (ja) | 2022-11-01 |
MA46200A (fr) | 2019-07-17 |
JP2019530654A (ja) | 2019-10-24 |
US20230159658A1 (en) | 2023-05-25 |
CR20190162A (es) | 2019-05-13 |
CN109661241A (zh) | 2019-04-19 |
WO2018047813A1 (en) | 2018-03-15 |
RU2019109464A (ru) | 2020-10-08 |
KR102560808B1 (ko) | 2023-07-27 |
MX2019002510A (es) | 2019-06-24 |
CA3035327A1 (en) | 2018-03-15 |
EP3509637A1 (en) | 2019-07-17 |
TWI786061B (zh) | 2022-12-11 |
KR20190044673A (ko) | 2019-04-30 |
TW201822815A (zh) | 2018-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019003989A2 (pt) | métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado | |
BR112016029316A2 (pt) | composição farmacêutica para uso na prevenção e/ou tratamento de doença que se desenvolve ou progride como um resultado da diminuição ou deficiência da atividade do fator de coagulação sanguínea viii e/ou fator de coagulação sanguínea ativado viii | |
BR112018074155A2 (pt) | anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo | |
BR112019023754A2 (pt) | anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica. | |
BR112017013599A2 (pt) | composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras. | |
BR112017020973A2 (pt) | método para tratar câncer em um paciente | |
BR112018012914A2 (pt) | composto, método para tratar, prevenir ou melhorar um ou mais sintomas de câncer, método para tratar, prevenir ou melhorar um ou mais sintomas de uma doença inflamatória e composição farmacêutica | |
BR112018075198A2 (pt) | método para o tratamento de câncer ou uma doença associada a patógeno, composição farmacêutica, e kit | |
BR112017016636A2 (pt) | formulação líquida estável para anticorpos monoclonais | |
BR112017016952A2 (pt) | terapia de combinação com fatores de coagulação e anticorpos multiespecíficos | |
BR112016030447A2 (pt) | diacorpo biespecífico de fc capaz de ligação imunoespecífica a um epítopo de pd-1 e a um epítopo de lag-3, composição farmacêutica, método para tratamento de câncer, e, método para tratamento de uma doença associada com a presença de um patógeno | |
BR112018011131A2 (pt) | terapia de combinação baseada em inibidores de sinal de pd-1 | |
BR112018000212A2 (pt) | uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer | |
BR112016029492A2 (pt) | método para tratamento de linfoma não hodgkin | |
BR112018068512A2 (pt) | métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3 | |
BR112017018328A2 (pt) | anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo | |
EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
BR112014031866A2 (pt) | Composição farmacêutica intramamária para utilização no tratamento ou prevenção da mastite em um mamífero não humano e composição farmacêutica de fosfomicina e de pelo menos um anti-microbiano | |
BR112018076639A2 (pt) | quimioterapias de combinação | |
BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
BR112017014793A2 (pt) | regime de dosagem para antagonistas de madcam | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112021008582A8 (pt) | Regime de dosagem de anticorpo anti-tigit para tratamento de câncer | |
BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |